FCGR2A and cancer: The upregulation of MHC class I and PD-L1 on cancer cells was also lost when D265A or LALA-PG mutations were introduced in the 2.5F-Fc antibody surrogate (Figures S3G and S3H).Treatment with 2.5F-Fc bearing LALA-PG mutations in the Fc domain to block both FcγR binding and complement activation (Lo et al., 2017) did not further blunt efficacy, suggesting complement does not play a major role.